Archived Medical News Stories

RSSArchived Drug Trial News Stories - March 2011

Date Title Comments Rating
2011-03-31 Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus 0 None
2011-03-31 Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s 0 None
2011-03-31 FDA grants Nile Fast Track designation for cenderitide post-acute development program 0 None
2011-03-31 Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder 0 None
2011-03-31 Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C 0 None
2011-03-31 Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV 0 None
2011-03-31 NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV 0 None
2011-03-31 Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting 0 None
2011-03-31 Positive outcomes from imatinib trial in both older and younger patients with CML 0 None
2011-03-31 Glasgow Professor discusses about new approach for CML treatment at UK conference 0 None
2011-03-31 CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel 0 None
2011-03-31 Boceprevir drug can help cure hard-to-treat hepatitis C 0 None
2011-03-31 Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC 0 None
2011-03-31 Three-drug cocktail more effective against hepatitis C virus 0 None
2011-03-31 Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting 0 None
2011-03-30 MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF 0 None
2011-03-30 Amgen announces top-line results from motesanib Phase 3 trial against NSCLC 0 None
2011-03-30 BioSante completes patient enrollment in LibiGel Phase III trial against HSDD 0 None
2011-03-30 Pharmasset commences PSI-7977 Phase 2b study against HCV 0 None
2011-03-30 Columbia Labs' PROCHIEVE Phase III trial results to be published in online medical journal 0 None
2011-03-30 SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting 0 None
2011-03-30 Positive preliminary results from Presidio's PPI-461 Phase 1b trial against HCV 0 None
2011-03-30 Positive results from Vertex VX-770 Phase 3 trial against CF 0 None
2011-03-30 Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis 0 None
2011-03-30 Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes 0 None
2011-03-29 New lung cancer drug starts human trials 0 None
2011-03-29 Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy 0 None
2011-03-29 Regado to present REG1 Phase 2b trial results against acute coronary syndromes at i2 Summit 0 None
2011-03-29 Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR 0 None
2011-03-29 Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma 0 None
2011-03-29 International Phase II trial to study LY2181308 efficacy in patients with lung cancer 0 None
2011-03-29 CytRx to present bafetinib preclinical study results at AACR Annual Meeting 0 None
2011-03-29 Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting 0 None
2011-03-28 Dementia & Alzheimer’s drug trial with sleep hormone melatonin 0 None
2011-03-28 PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB 0 None
2011-03-28 ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown 0 None
2011-03-28 Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes 0 None
2011-03-28 Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center 0 None
2011-03-28 Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease 0 None
2011-03-28 Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point 0 None
2011-03-28 Cancer drug Gleevec may hold promise against scleroderma: Study 0 5
2011-03-28 AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting 0 None
2011-03-28 NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS 0 None
2011-03-28 Genentech's Lucentis Phase III trials in DME meets primary endpoints 0 None
2011-03-25 XTL announces MinoGuard acquisition 0 None
2011-03-25 Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer 0 None
2011-03-25 Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients 0 None
2011-03-25 Isotechnika fourth quarter consolidated net loss increases to $2.42 million 0 None
2011-03-25 Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology 0 None
2011-03-25 Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries 0 None
2011-03-25 SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting 0 None
2011-03-25 Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke 0 None
2011-03-25 Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD 0 None
2011-03-25 Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease 0 None
2011-03-25 Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers 0 None
2011-03-25 Clinical trial to determine whether Crestor can prevent new colon tumors after surgery 0 None
2011-03-25 Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis 0 None
2011-03-24 Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting 0 None
2011-03-24 Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD 0 None
2011-03-24 Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting 0 None
2011-03-24 Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients 0 None
2011-03-24 Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder 0 None
2011-03-24 Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective 0 None
2011-03-24 Oramed reports successful completion of ORMD-0801 oral insulin toxicity study 0 None
2011-03-24 KaloBios commences KB004 Phase 1 trial in patients with leukemia 0 None
2011-03-23 Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery 0 None
2011-03-23 MnSOD oral drug can protect against lung cancer radiation therapy 0 None
2011-03-23 Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment 0 None
2011-03-23 Jefferson begins patient recruitment for new clinical trail to prevent colon cancer 0 None
2011-03-23 ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting 0 None
2011-03-23 Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA 0 None
2011-03-23 Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes 0 None
2011-03-23 FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia 0 None
2011-03-23 Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients 0 None
2011-03-23 Cellerant commences CLT-008 Phase I/II trial in patients with leukemia 0 None
2011-03-23 Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis 0 5
2011-03-23 Astellas announces positive results from mirabegron phase III trials against OAB 0 5
2011-03-23 Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI 0 None
2011-03-22 Five year course of tamoxifen can offer long-term benefit for women with breast cancer 0 None
2011-03-22 Positive results from Meda's Dymista Phase III trial in patients with SAR 0 None
2011-03-22 Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting 0 None
2011-03-22 CSL Behring presents Hizentra study data against PI at AAAAI meeting 0 None
2011-03-22 Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting 0 None
2011-03-22 Polypill may serve as viable option for developing countries to treat CVD risk prevention 0 None
2011-03-22 ACE, ARB combination therapy may increase risk of kidney failure, death 0 None
2011-03-22 BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint 0 None
2011-03-21 Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology 0 None
2011-03-21 Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer 0 None
2011-03-21 Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism 0 None
2011-03-21 NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis 0 None
2011-03-21 FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections 0 None
2011-03-21 Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain 0 None
2011-03-21 NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza 0 None
2011-03-21 United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension 0 None
2011-03-21 Advanced Cell Technology reduces 2010 debt to less than $1 million 0 None
2011-03-21 Medicago launches clinical development of seasonal flu vaccine 0 None
2011-03-21 Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema 0 None
2011-03-21 XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD 0 None
2011-03-21 Positive results from GDC-0449 Phase II clinical trial in advanced basal cell carcinoma 0 None
2011-03-21 CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma 0 None
2011-03-21 Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint 0 None
2011-03-19 BioMarin announces preliminary results from ADAPT in patients suffering from PKU 0 None
2011-03-19 The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence 0 None
2011-03-19 Quark Pharmaceuticals receives results from Phase 2 trial of PF-04523655 in patients with DME 0 None
2011-03-19 Polaris initiates ADI-PEG 20 Phase 2 trial in patients with malignant mesothelioma 0 None
2011-03-18 Science journal publishes CYTK preclinical cardiac myosin activation research results 0 None
2011-03-18 KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction 0 None
2011-03-18 Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma 0 None
2011-03-18 FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease 0 None
2011-03-17 CytRx commences INNO-206 Phase 1b trial in advanced solid tumors 0 None
2011-03-17 PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting 0 None
2011-03-17 New lozenge clinical trial for dry mouth treatment 1 None
2011-03-17 HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers 0 None
2011-03-17 Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers 0 None
2011-03-17 Specific type of selenium supplement may help prevent cancer 0 None
2011-03-17 The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD 0 4
2011-03-16 Fibrocell Science submits azficel-T final study report to FDA 0 None
2011-03-16 RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold 0 None
2011-03-16 Cortex enters agreement with Biovail to regain AMPAKINE assets and rights 0 None
2011-03-16 NIH awards TriLink $100,000 Phase I SBIR Grant to develop Hot Start approach for Ligase Chain Reaction 0 None
2011-03-16 Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome 0 None
2011-03-16 Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment 0 None
2011-03-16 AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation 0 None
2011-03-16 Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis 0 None
2011-03-16 iTherX commences ITX-5061 Phase 1b study in patients with HCV 0 None
2011-03-15 Apeiron in antitumor substances deal with Cleveland Clinic 0 None
2011-03-15 Anavex to commence phase I clinical trial in Alzheimer’s disease 0 None
2011-03-15 Additional research needed for oral PrEP to treat HIV 0 None
2011-03-15 CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial 0 None
2011-03-15 Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint 0 5
2011-03-15 Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy 0 None
2011-03-15 Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS 0 None
2011-03-15 Positive top-line results from IPX066 Phase III study in patients with PD 0 None
2011-03-14 Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas 0 None
2011-03-14 Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder 0 None
2011-03-14 Positive results from azide drug-loaded Emulsiphan preclinical toxicity study 0 None
2011-03-14 Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development 0 None
2011-03-14 KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism 0 None
2011-03-14 Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder 0 None
2011-03-14 Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides 0 None
2011-03-14 Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis 0 None
2011-03-14 ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV 0 None
2011-03-14 BioInvent commences BI-204 phase II study in patients with acute coronary syndrome 0 None
2011-03-14 Combination therapy may overcome Herceptin-resistant breast cancer 0 None
2011-03-12 Alzheimer's vaccine - First evidence for efficacy 0 5
2011-03-11 Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint 0 None
2011-03-11 Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints 0 None
2011-03-11 Inhibitex fourth quarter net loss increases to $7.0 million 0 None
2011-03-11 Synta fourth-quarter total collaboration revenue decreases to $3.0 million 0 None
2011-03-11 Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC 0 None
2011-03-11 Genentech announces positive outcomes from Lucentis Phase III trial against DME 0 None
2011-03-11 Sildenafil helps improve exercise performance in children with congenital heart disease 0 None
2011-03-10 Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults 0 None
2011-03-10 Positive results from exenatide phase 2 study in patients with type 2 diabetes 0 None
2011-03-10 Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma 0 None
2011-03-10 Idera reports $6.0 million net loss for fourth quarter 2010 0 None
2011-03-10 Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris 0 None
2011-03-10 Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases 0 None
2011-03-10 CTI announces final pixantrone clinical trial design for treatment of DLBCL 0 None
2011-03-10 FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids 0 None
2011-03-10 Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia 0 None
2011-03-10 TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis 0 None
2011-03-09 NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease 0 None
2011-03-09 Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease 0 5
2011-03-09 ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL 0 None
2011-03-09 Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting 0 None
2011-03-09 Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO 0 5
2011-03-09 Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study 0 None
2011-03-09 Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting 0 3
2011-03-09 FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly 0 None
2011-03-09 FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease 0 None
2011-03-09 Unique gene therapy to combat Parkinson's disease 0 None
2011-03-09 Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD 0 None
2011-03-08 Treatment with sildenafil significantly reduces RP in patients with scleroderma 0 None
2011-03-08 Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma 0 None
2011-03-08 Conflicts of interest overlooked in drug trial reviews: Study 0 None
2011-03-08 Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA 0 None
2011-03-08 Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions 0 None
2011-03-08 BMY to present new Phase II data on investigational hepatitis C compounds at ILC 0 None
2011-03-08 Fumaric acid salts may protect against Multiple Sclerosis 0 None
2011-03-08 New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts 0 1
2011-03-08 Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression 0 None
2011-03-07 Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer 0 None
2011-03-07 USPTO grants patent to Symphogen's Sym004 to treat solid tumors 0 None
2011-03-07 Duchenne Parent Project awards grant to AMT for DMD gene therapy 0 None
2011-03-05 Researchers use qMRI to confirm effect of CS treatment in patients with OA 0 None
2011-03-05 Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study 0 None
2011-03-05 Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints 0 None
2011-03-04 Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI 0 None
2011-03-04 Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75% 0 None
2011-03-04 BioSante vaccine increases median survival of resected pancreatic cancer patients 0 None
2011-03-04 Ekomed to collaborate with Immune Network and Immunitor for further research of Immunoxel/Dzherelo 0 None
2011-03-04 Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion 0 None
2011-03-04 Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL 0 None
2011-03-04 Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment 0 None
2011-03-03 Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA 0 None
2011-03-03 Clinical trials in Australia take too long– need uniform standards: Report 0 None
2011-03-03 Glenmark Generics granted final FDA approval for generic Xyzal ANDA 0 None
2011-03-03 Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA 0 None
2011-03-03 Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer 0 None
2011-03-03 Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV 0 None
2011-03-03 Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal 0 None
2011-03-03 Depomed completes patient enrollment in Breeze 3 Serada Phase 3 trial to treat menopausal hot flashes 0 None
2011-03-03 Lixte receives $244,479.25 U.S. government grant for QTDP program 0 None
2011-03-03 Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV 0 None
2011-03-03 Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine 0 None
2011-03-03 EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML 0 None
2011-03-03 Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack 0 None
2011-03-02 FDA accepts Handa's generic DEXILANT ANDA for review 0 None
2011-03-02 Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI 0 None
2011-03-02 Mylan confirms lawsuit relating to Estradiol Transdermal System ANDA 0 None
2011-03-02 Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder 0 None
2011-03-02 Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder 0 None
2011-03-02 Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses 0 None
2011-03-02 Geron's hESC derived GRNCM1 halts remodeling process and preserves cardiac function in acute heart damage 0 None
2011-03-02 NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer 0 None
2011-03-02 OneWorld Health receives FDA clearance for iOWH032 phase 1 trials to treat secretory diarrhea 0 None
2011-03-01 Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis 0 None
2011-03-01 Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL 0 None
2011-03-01 Tenofovir gel more effective than oral tablet for HIV treatment: Study 0 None
2011-03-01 Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI 0 None


221 posts
11 raters